meta_pixel
Tapesearch Logo
Log in
Viewsroom

Novo Nordisk is Denmark’s big little problem

Viewsroom

Reuters

News

4.458 Ratings

🗓️ 26 March 2026

⏱️ 22 minutes

🧾️ Download transcript

Summary

As war rages and Donald Trump looms, a recent election featured little mention of the ailing $164 bln drugmaker, once so successful it distorted economic figures. In this week’s Viewsroom, Breakingviews columnists discuss the future of weight loss pills, and Novo’s place in it. (This episode has been corrected to remove a statement that Novo Nordisk’s Wegovy pill needs to be refrigerated.) Novo Nordisk's illness offers painful lessons Novo Nordisk’s falling knife is still gathering speed Obesity pills are shaky Hail Mary for Novo Nordisk Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising. Learn more about your ad choices. Visit megaphone.fm/adchoices

Transcript

Click on a timestamp to play from that location

0:00.0

When the tax year ends on the 5th of April, valuable tax allowances may be lost simply because people left things too late.

0:08.0

Thankfully, Vanguard is here to help you make well-consider decisions, not rushed ones.

0:14.0

Their tax year-end hub is full of clear guidance, helpful tools and timely reminders to help you understand your allowances and give your investments

0:22.5

the best chance to grow.

0:24.0

Search Vanguard investor to learn more.

0:26.2

When investing, your capital is at risk.

0:28.5

Tax rules apply.

0:30.6

The views expressed on this podcast are those of the participants, not of Rojers News.

0:39.0

It's a very busy week in Denmark.

0:42.0

On Tuesday, voters went to the polls to elect a new government.

0:45.8

And on Thursday, Nova Nordisk, the troubled Danish drugmaker, is having its annual general meeting.

0:52.7

I've come to Copenhagen, hoping to learn more about how the drug maker is planning to stage a comeback,

0:58.7

how it will compete with its rival Eli Lilly, which is nearing a trillion dollar valuation,

1:04.1

and how the conflict in Iran and looming economic challenges will impact demand for weight loss drugs.

1:10.6

We're recording this on Wednesday, so stay tuned for this week's Viewsroom.

1:17.4

It's Amy.

1:18.8

And it's Jonathan.

1:19.6

And this is a views room.

1:20.6

Your weekly dive into the biggest topics in business, corporate finance and economics.

1:25.2

And Amy, okay, look, I'm very excited.

1:27.3

You're in Copenhagen. My wife is

1:29.0

Danish, lots of Danish in-laws. You've got to hit pot or coffee. You've got to go across the

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from Reuters, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Reuters and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.